INTRODUCTION
Iron deficiency is the most common nutritional deficiency worldwide; it affects 1.6 billion people (nearly a quarter of the world's population). 1 Lack of iron supplementation during pregnancy and postpartum hemorrhage (PPH) are another important causes of postpartum anemia (PPA). Randomized clinical trials have shown that lack of prenatal iron supplementation is associated with low ferritin stores throughout the postpartum period. 1 This is because pregnancy requires about 1000 mg of additional iron, which cannot be met by the typical diet. 2, 3 These women with Iron Deficiency Anemia (IDA) especially during the second and third trimester of pregnancy are more likely to suffer from postpartum hemorrhage (PPH) and further worsen anaemia and its related complications. PPH is also an important cause of postpartum anemia.
Iron was given intramuscularly cause considerable pain, skin staining, bleeding, tissues necrosis, arthralgia, myalgia, sterile abscess atrophy and sarcoma formation.
So to treat these conditions we require a new mode of iron therapy with better efficacy, less side effects and better compliance. Intravenous iron carboxymaltose therapy seems to be a safe, convenient and more effective method for treating anemia during postpartum period than intravenous iron sucrose therapy. 8 Aims and objective: Comparative study of efficacy and safety of single dose intravenous iron carboxymaltose and multi dose intravenous iron sucrose therapy in postpartum women of sever iron deficiency anemia.
METHODS
Study was carried out in the department of obstetrics and gynaecology, S. N. medical college Agra during 2 year duration from October 2012 to October 2014.
The study comprised of 100 cases which are to be randomly distributed into two groups consisting of 50 cases each.
Group -A: 50 cases in this group receive intravenous iron carboxymaltose therapy.
Group -B: 50 cases in this group receive intravenous iron sucrose therapy.
Inclusion criteria
All normal delivered and caesarean delivered patients with IDA Exclusion criteria- Patients with hemoglobin levels more than 7gm%.
 Normal serum iron levels. 
Iron therapy
Group A: Intravenous injections (Iron carboxymaltose complex)
They are available as ampules of 10 ml containing 500 mg of elemental iron. Ferric carboxymaltose injection administered as follows: Iron sucrose complex was given as 200 mg elemental iron (2 ampules of 5 ml) in 100 ml of 0.9% normal saline infusion over 30 min. alternate days up to 5 days.
RESULTS
The mean age in group A was 25.30 years and mean age in group B was 25.56 years ( Table 2 ). In group A 20% cases were primiparous and 80% cases were multiparous ( Table 4) .
Majority of the cases belonged to lower middle status (class 4) according to modified B. J. Prasad classification in both the groups (Table 3) .
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The mean hemoglobin level before starting therapy in group A was 6.14 gm/dl and in group B was 6.06 gm/dl (Table 5) , there was an increase of 2.52 gm/dl in hemoglobin level after 2 weeks of therapy and mean hemoglobin level was 8.66 gm/dl in group A and in group B there was an increase of 1.95 gm/dl in hemoglobin level and the hemoglobin level was 8.01 gm/dl (Table 6 ).
This difference further increased at 4 weeks after therapy. The hemoglobin level was 10.01 gm/dl in group A (rise of 3.95 gm/dl) at 4 weeks of therapy and in group B hemoglobin level was 9.38 gm/dl (rise of 3.32 gm/dl) ( Table 7) . In group A, 84% cases achieved the target hemoglobin at 8 weeks after therapy and 100% cases achieved target hemoglobin at 12 weeks after therapy. In group B, 80% cases achieved the target hemoglobin at 8 weeks after None of the case in both the groups had grade II adverse effects. So we can say that the intravenous iron carboxymaltose therapy is more effective and safe therapy to treat iron deficiency anemia during postpartum period.
DISCUSSION
In obstetrics, red blood cell transfusions currently account for 3-4% of all transfusion events and the majority of these occur following Post-Partum Hemorrhage (PPH) in UK. 9 PPH is the leading cause of maternal mortality in obstetrics, and is estimated to occur at a rate of 13.1%. 10 Despite its enormous clinical utility, RBC transfusion is a treatment with well described adverse events and risk, and should ideally be avoided. Additionally blood is both costly and in ever increasingly short supply. [11] [12] [13] In the present study, the cases selected in both the groups were comparable in terms of age, parity, and socioeconomic status. The mean hemoglobin level achieved and rate of increase in intravenous iron carboxymaltose group was significantly higher. S. Bhandari also supported that intravenous ferric carboximaltose is cost effective as it significantly reduces need of blood transfusion and its complications. 14, 15 The incidence of adverse effects was also significantly lower in intravenous iron carboxymaltose group in our study. C. Breymann et al. and R. Eneshaliev et al. showed in their study that ferric carboximaltose in iron deficiency anemia in patients of inflammatory bowel disease as well as in obstetrics is quite safe and effective. 16 ,17
CONCLUSION
Thus we can conclude that intravenous iron carboxymaltose therapy is safe, convenient, more effective and faster acting than intravenous iron sucrose therapy for the treatment of severe iron deficiency anemia during postpartum period. 18, 19 
